期刊
MOLECULAR ONCOLOGY
卷 9, 期 2, 页码 503-512出版社
WILEY
DOI: 10.1016/j.molonc.2014.10.005
关键词
Ovarian cancer; Proximity ligation assay; MUC16; MUC1; Glyco-mucin profile
类别
资金
- Programa Operacional Ciencia e Inovacao do Quadro Comunitario de Apoio III
- FEDER [PTDC/SAU-ONC/117216/2010]
- FCT [SFRH/BD/60536/2009]
- Programa Operacional Regional do Norte (ON.2 - O Novo Norte), under Quadro de Referencia Estrategico Nacional (QREN) [NORTE - 07-0124-FEDER-000024]
- Fundo Europeu de Desenvolvimento Regional (FEDER)
- Kirsten og Freddy Johansen Fonden
- A.P. Moller og Hustru Chastine McKinney Mollers Fond til Almene Formaal
- Novo Nordisk Foundation
- Danish Research Councils
- programme of excellence from the University of Copenhagen
- Danish National Research Foundation [DNRF107]
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-ONC/117216/2010, SFRH/BD/60536/2009] Funding Source: FCT
The CA125 assay detects circulating MUC16 and is one of the most widely used cancer biomarkers for the follow-up of ovarian cancer. We previously demonstrated that detection of aberrant cancer-associated glycoforms of MUC16 as well as MUC1 in circulation could improve the yield of these serum assays. Our aim was to refine ovarian cancer biomarkers by detection of aberrant glycoforms (Tn, STn, and T) of MUC16 and MUC1 in ovarian cancer tissue using Proximity Ligation Assays (PLA). We studied two series of serous ovarian tumours, a pilot series of 66 ovarian tumours (27 cystadenomas, 16 borderline tumours and 23 adenocarcinomas) from Centro Hospitalar S. Joao, Porto and a validation series of 89 ovarian tumours (17 cystadenomas, 25 borderline tumours and 47 adenocarcinomas) from the Portuguese Institute of Oncology Francisco Gentil, Lisbon. PLA reactions for MUC16/Tn, MUC16/STn, MUC1/Tn and MUC1/STn were negative in benign lesions but often positive in borderline and malignant lesions, in both series. An even better yield was obtained based on positivity for any of the four glyco-mucin profiles, further increasing sensitivity to 72% and 83% in the two series, respectively, with 100% specificity. The strategy is designated glyco-mucin profiling and provides strong support for development of PLA-based serum assays for early diagnosis. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据